Well, IOVA are using 'bulk' TIL, but in the (near) future plan to use a PD-1+ population [1].
However, it has been shown that CD39, rather than PD-1, accurately distinguish between reactive (CD39+) and unrelated (CD39-) CD8+ T-cell populations [2]. In line with the paper, another showed that co-expression of both CD39 and CD103 favoured the identification of tumour-reactive T-cells [3]. One company (AgonOx*) is working on the latter, and has a collaboration with PHIO.
Another problem is that on certain populations, such as neoantigen-experienced terminally differentiated effector memory cells, PD-1 is either not expressed, or expressed at very low levels [4].
Refs:
1 https://www.jci.org/articles/view/73639
2 https://www.nature.com/articles/s41586-018-0130-2
3 https://www.nature.com/articles/s41467-018-05072-0
4 https://onlinelibrary.wiley.com/doi/full/10.1002/cyto.a.22351
* These double positive populations are highly enriched within both primary and metastatic lesions and have a broad repertoire of neoantigen-reactive TCRs. Also, they are able to find them in the majority of solid tumours sampled (~90%). The only difference is the frequency, with some higher, while others are lower.
More importantly, they can sort and culture as few as 2000-10,000 and grow them to billions in a five-week span. With improvements to ex vivo expansion, and using NKTR's bempeg over high-dose IL-2, the depth and duration of response should be greatly improved.
Initial indications could be SCHNC, NSCLC, melanoma, ovarian, RCC, bladder, cervical, HCC, prostate, breast, GBM and/or rectal.
Recent IOVA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:56:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:54:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:53:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:52:10 PM
- Iovance Biotherapeutics to Present at Upcoming Conferences • GlobeNewswire Inc. • 09/03/2024 09:00:18 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:16:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:10:32 PM
- Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 • GlobeNewswire Inc. • 08/08/2024 08:01:32 PM
- Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024 • GlobeNewswire Inc. • 07/29/2024 08:01:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/19/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 12:01:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 12:01:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 12:00:18 AM
- Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma • GlobeNewswire Inc. • 06/28/2024 11:00:00 AM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/21/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:03:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 09:15:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:07:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:05:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:04:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:01:02 PM
- Iovance Biotherapeutics to Present at Upcoming Conferences and Events • GlobeNewswire Inc. • 05/24/2024 08:01:00 PM
- Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM